title: Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
abstract: OBJECTIVE
  To compare structural outcomes, visual function, refraction, and frequency of follow-up for infants with type 1 retinopathy of prematurity in zone I or zone II posterior treated with intravitreal bevacizumab (IVB) versus laser.
  
  
  METHODS
  The medical records of infants treated with IVB or laser photocoagulation at our institution from January 2009 to May 2013 were retrospectively reviewed. Only infants with a minimum of 6 months' follow-up were included. Outcome measures were structural outcome, visual acuity, and spherical equivalent (SE) at corrected age of 1 year. The frequency of follow-up visits during 9 months after treatment was evaluated.
  
  
  RESULTS
  A total of 23 eyes of 13 infants were treated with IVB and 22 eyes of 12 infants were treated with laser. There was no statistically significant difference in gestational age or birth weight between groups. None developed unfavorable structural outcome. Mean visual acuity was 0.99 ± 0.38 logMAR for the IVB group and 0.71 ± 0.36 logMAR for the laser group (P = 0.34; 95% CI, -0.52 to 0.19). Mean spherical equivalent was -3.57 ± 6.19 D for the IVB group and -6.39 ± 4.41 D for the laser group (P = 0.33; 95% CI, -7.19 to 2.49). In the IVB group, infants had an average of 16.00 ± 6.00 follow-up visits; in the laser group, 6.00 ± 3.00 (P < 0.0001).
  
  
  CONCLUSIONS
  Both treatments resulted in good structural outcome, and no difference in visual acuity or refraction. However, more frequent follow-up was observed in the IVB group.
authors.affiliation: Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: Maram
authors.initials: M
authors.lastname: Isaac
authors.affiliation: Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Kamiar
authors.initials: K
authors.lastname: Mireskandari
authors.affiliation: Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada. Electronic address: nasrin.tehrani@sickkids.ca.
authors.forename: Nasrin
authors.initials: N
authors.lastname: Tehrani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation; D012029:Refraction, Ocular / Q000502:physiology; D012160:Retina / Q000503:physiopathology; D012178:Retinopathy of Prematurity / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab